Lunit
KOSDAQ-listed Korean AI for breast and lung cancer screening
Overview
Lunit is a KOSDAQ-listed Korean medical-AI company selling FDA-cleared cancer-screening software: INSIGHT for chest X-ray, mammography and tomosynthesis, and SCOPE for digital pathology and biomarker analysis, deployed across 330+ imaging sites worldwide.
What you can produce with Lunit
- INSIGHT CXR — chest X-ray AI detection
- INSIGHT MMG — 2D mammography cancer detection
- INSIGHT DBT — 3D tomosynthesis malignancy scoring
- INSIGHT Risk — breast-cancer risk prediction (FDA 510(k) filed)
- SCOPE — digital pathology and PD-L1 biomarker analysis
- FDA-cleared and CE-marked across multiple products
- KOSDAQ-listed (328130), public quarterly financials
- Distribution partnerships with GE Healthcare, Philips, Fujifilm
ASEAN Perspective
Lunit in Southeast Asia
ASEAN-region availability and pricing notes coming soon. Drop the editorial team a note via /contact/ if you can supply local context (Singapore/Malaysia/Indonesia/Thailand/Vietnam).
Lunit is the most clinically validated medical-AI company to come out of Korea, and one of the few in the category with real revenue rather than just pilot deployments — Q1 2026 revenue hit 24 billion won, up nearly 25% year over year, and its Volpara Health subsidiary added another 15.7 billion won. INSIGHT CXR, MMG and DBT cover chest X-ray, 2D mammography and tomosynthesis with FDA clearances now extending to a breast-cancer risk-prediction model; SCOPE applies AI to digital pathology and PD-L1 biomarker scoring for immunotherapy decisions, with research partnerships including AstraZeneca and CellCarta.
It sells into hospitals and pharma through distribution deals with GE Healthcare, Philips and Fujifilm, procurement cycles and per-institution pricing, not a self-serve product — there's no public API or free tier, and adoption depends on radiologists and pathologists trusting the workflow integration, not a marketing page. For imaging centers evaluating cancer-screening AI with an actual regulatory and evidence trail behind it, Lunit is a top-tier option; it has no relevance outside clinical radiology and pathology.
What people say
Lunit doesn't have retail-style reviews — it sells regulated medical software to hospitals and pharma companies, so the evidence base looks more like financial disclosures and peer-reviewed validation studies than star ratings. As a KOSDAQ-listed company (ticker 328130, listed July 2022) it publishes quarterly financials: Q1 2026 revenue reached 24 billion won, up 24.7% year over year, with its Volpara Health subsidiary (Lunit International) contributing 15.7 billion won, up 34.1%. Korea Biomed has reported the company is targeting profitability by 2027 and has ruled out a rights offering to get there.
On the regulatory side, INSIGHT MMG's mammography AI is cited at 96% accuracy for detecting malignant lesions in company materials, and the company has kept adding FDA clearances — most recently pursuing 510(k) clearance for INSIGHT Risk, a breast-cancer risk-prediction model, and clearing next-generation 3D mammography AI in April 2026. Distribution runs through hardware partnerships with GE Healthcare, Philips and Fujifilm rather than direct sales, and PR Newswire/Morningstar coverage puts deployment at over 330 sites and 1 million annual screenings for the breast-imaging line alone as of April 2026.
On the pathology side, SCOPE's biomarker AI has driven research revenue from pharma partners — collaboration income with companies like AstraZeneca is reported to be growing from roughly 4 billion won toward a projected 10-20 billion won over the following year — and a September 2025 partnership with Canada's CellCarta extended SCOPE into clinical-trial pathology workflows.
What's missing from public sources is independent comparative benchmarking against other FDA-cleared cancer-AI vendors — the accuracy figures available are largely company-published or drawn from Lunit-sponsored studies rather than adjudicated head-to-head trials, which is a reasonable caveat for hospital buyers to raise during procurement despite the otherwise strong clinical and commercial track record.
Founded in 2013 and listed on KOSDAQ since July 2022 at roughly $42 million raised, Lunit's market capitalization has grown substantially since — public trackers put it near 1.2 trillion won as of mid-2026, up from around 420 billion won shortly after listing — a trajectory investors have read as validation of the AI-diagnostics category more broadly, not just this one vendor.
Summary of public user & expert reviews, compiled by RECATOOLS.
About this listing
This entry was compiled from publicly available data including Lunit's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Lunit unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Lunit directly →
Spotted something out of date? Suggest an update →
Alternatives to Lunit
More in Healthcare
